Vraylar Can Be Used With Caution in Patients With a History of Seizures
Vraylar (cariprazine) may be prescribed to patients with a history of seizures, but requires close monitoring as it can lower the seizure threshold and increase seizure risk, particularly in those with pre-existing seizure disorders.
FDA-Approved Labeling Guidance
The FDA label for Vraylar explicitly addresses seizure risk 1. The key warning states: "Like other antipsychotic drugs, VRAYLAR may cause seizures. This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold." 1
Importantly, the FDA label notes that "conditions that lower the seizure threshold may be more prevalent in older patients" 1, making age an additional consideration when prescribing to patients with seizure history.
Clinical Decision-Making Algorithm
When to Consider Vraylar Despite Seizure History:
- Seizures are well-controlled on current antiepileptic medications
- Patient has compelling psychiatric indication (treatment-resistant schizophrenia, bipolar disorder, or major depressive disorder)
- Benefits of psychiatric stabilization outweigh seizure risk
- Close monitoring is feasible
When to Exercise Greater Caution:
- Uncontrolled or recent seizures (within past year)
- Patient not on antiepileptic medications despite seizure history
- History of status epilepticus
- Multiple seizure risk factors present (elderly, brain injury, alcohol withdrawal)
- Limited access to neurological follow-up
Practical Management Recommendations
Before Initiating Vraylar:
- Document seizure history details: frequency, last seizure date, triggers, current antiepileptic regimen
- Verify antiepileptic medication adherence and therapeutic levels if applicable
- Coordinate with neurology if seizures are not optimally controlled
- Assess additional risk factors: alcohol use, other CNS-active medications, sleep deprivation
During Treatment:
- Start at lowest effective dose and titrate slowly
- Monitor closely for seizure activity during dose initiation and increases
- Educate patient and family about seizure warning signs
- Avoid abrupt discontinuation of antiepileptic medications
- Counsel on seizure precautions: avoid driving until stable, avoid high-risk activities
If Seizure Occurs on Vraylar:
According to stroke and seizure management guidelines, new-onset seizures should be treated with short-acting medications (e.g., lorazepam IV) if not self-limited 2. However, a single seizure does not automatically require long-term anticonvulsant therapy 2. The decision to continue Vraylar should involve:
- Neurology consultation
- Risk-benefit reassessment
- Consideration of alternative antipsychotics with lower seizure risk
- If continuing Vraylar, addition or optimization of antiepileptic therapy
Context From Antipsychotic Class Effects
While the provided guidelines focus primarily on traditional antiepileptic management 3, 4, 2, 4, 5, the principle that antipsychotics as a class can lower seizure threshold is well-established. The FDA labeling for Vraylar places it within this class effect 1.
Key Caveats
- No absolute contraindication exists for seizure history in the FDA labeling 1—the only contraindication is hypersensitivity to cariprazine
- Seizure risk appears dose-related based on clinical trial data showing extrapyramidal symptoms increased with higher doses 6, 7
- Metabolic neutrality of Vraylar 6, 8 may be advantageous, as some antiepileptic medications (particularly valproate) cause metabolic effects
- Long half-life of active metabolite (DDCAR: 1-3 weeks) 6 means effects persist long after discontinuation—important if seizures develop
Bottom Line
Vraylar is not contraindicated in patients with seizure history, but requires individualized risk assessment, close monitoring, and coordination with neurology when appropriate. The decision should weigh the severity of psychiatric illness against seizure control status, with preference for patients whose seizures are well-controlled on stable antiepileptic regimens.